SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-21-029557
Filing Date
2021-11-22
Accepted
2021-11-22 16:05:49
Documents
16
Period of Report
2021-10-22
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 62747
2 ex99-2.htm EX-99.2 308316
3 ex99-3.htm EX-99.3 234718
4 ex99-4.htm EX-99.4 185600
  Complete submission text file 0001493152-21-029557.txt   1097724

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sabs-20211022.xsd EX-101.SCH 3878
6 XBRL DEFINITION FILE sabs-20211022_def.xml EX-101.DEF 27874
7 XBRL LABEL FILE sabs-20211022_lab.xml EX-101.LAB 37058
8 XBRL PRESENTATION FILE sabs-20211022_pre.xml EX-101.PRE 26492
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 5849
Mailing Address 300 W. 41ST STREET SUITE 202 MIAMI BEACH FL 33140
Business Address 300 W. 41ST STREET SUITE 202 MIAMI BEACH FL 33140 (305) 204-3338
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39871 | Film No.: 211432542
SIC: 2836 Biological Products, (No Diagnostic Substances)